Impax Defeats FTC Pay-For-Delay Complaint, Helped By Status As Sole Marketer Of Generic Opana ER
Executive Summary
FTC Chief Administrative Law Judge finds procompetitive benefit of Endo-Impax patent settlement agreement outweighs unjustified no-authorized generic provision.
You may also be interested in...
FTC Rules Impax $112mn Pay-For-Delay Deal With Endo Was Illegal
Agreeing a deal that it would not face an authorized generic during its 180-day market exclusivity for generic Opana ER contributed to Amneal's Impax striking an illegal pay-for-delay settlement, the FTC is alleging
Will Teva's Deal With FTC Change Future Patent Litigation Settlements?
Settlement reflects existing landscape in which companies are avoiding no-authorized generic commitments, and may harbinger FTC's shift to other issues.
Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals
Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.